Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
My north star: We disclose—fast, fully, and on our terms. The “wait for more data” option is a mirage. It exposes the company to criminal liability under FDA adverse-event reporting rules, potential DOJ investigation, securities fraud charges, and derivative litigation that could destroy the firm.Read the full answer
48-Hour Action Plan: Patient Safety First Critical Reality Check First Your legal team's "6 months" likely refers to a full label revision, not initial safety signal reporting. FDA requires serious unexpected adverse events reported within 15 days (7 days if fatal).Read the full answer